RxDoctor Payments Data

Peter Johnson, MD

Cardiovascular Disease · Decatur, ALNPI 1801008776

Payments from drug & device makers

$5,598in general payments, 2019–2025

Across 398 payments — averaging $14.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Amgen$542
  • Pfizer$476
  • Merck$457
  • Novo Nordisk$422
  • Johnson & Johnson$420
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$5,598100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,598 in reported general payments places this provider in the 60th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$227,502
Medicare patients
1,217
Services billed
3,689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban826$691,813
EntrestoSacubitril/Valsartan303$269,446
FarxigaDapagliflozin Propanediol243$163,203
JardianceEmpagliflozin177$157,617
XareltoRivaroxaban76$79,761
Repatha SyringeEvolocumab33$25,569
Repatha SureclickEvolocumab27$17,865
Metoprolol Succinate810$14,997
MultaqDronedarone Hcl11$13,070
BrilintaTicagrelor17$10,101
Praluent PenAlirocumab16$9,552
VascepaIcosapent Ethyl16$8,738
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,669
VerquvoVericiguat12$8,551
Atorvastatin Calcium661$8,072

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$476$691,813826 claims
NovartisEntresto$1,312$269,446303 claims
AstraZenecaFarxiga, Brilinta$268$173,304260 claims
Boehringer IngelheimJardiance$315$157,617177 claims
Johnson & JohnsonXarelto$420$79,76176 claims
Sanofi-aventis U.S. LLCMultaq$298$13,07011 claims
MerckVerquvo$457$8,55112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Decatur

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →